A phase II trial of split, low-dose docetaxel and low-dose capecitabine: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer

Orlando Silva, Gilberto Lopes, Daniel Morgenzstern, Christopher Lobo, Philomena Doliny, Edgardo Santos, Sakher Abdullah, Umang Gautam, Isildinha Reis, Catherine Welsh, Joyce Slingerland, Judith Hurley, Stefan Gluck

Research output: Contribution to journalArticle

11 Scopus citations

Fingerprint Dive into the research topics of 'A phase II trial of split, low-dose docetaxel and low-dose capecitabine: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences